Determination of Adequate TUberculosis Regimen in Adults and adolescents hospitalised with HIV-associated severe immune suppression – NCT04738812
Last-minute news: an oral presentation of the main results of the DATURA trial will be given at the CROI conference as part of the session entitled ‘Beyond the virus: the expanding landscape of HIV-associated conditions‘ on 23 February 2026.
Follow-up of participants in the DATURA trial was completed in November 2025. The last visits took place on October 30 in Guinea, November 3 in Mozambique, November 5 in Cameroon and Uganda, November 10 in Cambodia, and November 12 in Continue reading Finalisation of participant follow-up
Please click on the post title to find the latest newsletter for 2025.
Participant enrollment in the DATURA study was completed in December 2024. However, participants will continue to be monitored until their final trial visit, which will occur 48 weeks after the initiation of anti-TB treatment. The last visit for the final Continue reading Finalization of Participant Enrollment
The first face-to-face DATURA joint Project Steering Committee (PSC) and Data and Safety Monitoring Board (DSMB) meeting took place on July 7-9, 2024 in Montpellier, France. Around 40 people, members of the 2 committees together with representatives of all participating Continue reading First joint Project Steering Committee and Data and Safety Monitoring Board Meeting in 7-9 July 2024.
Please click on the post to find the latest newsletter of 2024.
It is with great pleasure to announce that all of the four trial sites in Africa have started to enroll patients in the DATURA program. The trial sites are located in Guinea, Cameroon, Zambia and Uganda. The latter received its Continue reading All African trial sites have completed their first patient enrolment